-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

615.O1.6 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML

Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, real-world evidence
Monday, December 11, 2023: 4:30 PM-6:00 PM
San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Moderators:
Irum Khan, MD, Northwestern and Christoph Röllig, MD, MSc, Medizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden
Disclosures:
Röllig: Servier: Consultancy, Honoraria; BMS: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding.
Data on intensive induction chemotherapy regimens for patients with acute myeloid leukemia will be presented, with a focus on the addition of venetoclax to many of the backbone therapies. Addition of a novel FLT3 inhibitor to backbone intensive chemotherapy will also be highlighted.
4:30 PM

Hunault-Berger Mathilde1*, Cécile Pautas, MD2*, Sarah Bertoli3*, Pierre-Yves Dumas, MD, PhD4*, Emmanuel Raffoux, M.D.5*, Tony Marchand, MD6*, Marie Anne Hospital7*, Mael Heiblig8*, Sylvain Chantepie, MD9*, Martin Carré, MD10*, Pierre Peterlin11*, Emilie Lemasle, MD12*, Célestine Simand, MD, PhD13*, Maria Pilar Gallego Hernanz, MD14*, Anne Huynh, MD15*, Edouard Forcade, MD, PhD16*, Raynier Devillier, MD, PhD17*, Stéphanie Nguyen Quoc, MD, PhD18*, Nicolas Duployez, PharmD, PhD19*, Isabelle Luquet, MD20*, Dominique Penther, MD21*, Karine Celli-Lebras, RN22*, Ariane Mineur23*, Claude Gardin, MD, PhD24*, Gerard Socié5, Jean-Yves Cahn, MD10*, Norbert Ifrah, MD, PhD1, Norbert Vey, MD25, Regis Peffault De Latour5*, Eric Delabesse, MD, PhD26*, Claude Preudhomme, PharmD, PhD27*, Jean-François Hamel, PhD28*, Arnaud Pigneux, MD, PhD4*, Christian Recher, MD, PhD29* and Hervé Dombret, MD, PhD5

1Hematology Department, CHU Angers, Angers, France
2Hôpital Henri Mondor, Hematology Department, AP-HP, Créteil, France
3IUCT-Oncopole, Hematology Department, CHU TOULOUSE, Toulouse, France
4Hôpital Haut-Lévèque, Hematology Department, CHU Bordeaux, Pessac, France
5Hôpital Saint-Louis, Hematology Department, AP-HP, Paris, France
6Hematology Department, CHU Rennes, Rennes, France
7Hematology Department, Institut Paoli-Calmettes, Marseille, France
8Hematology Department, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
9Institut d'Hématologie, CHU de Caen, Caen, France
10Hematology Department, CHU Grenoble, Grenoble, France
11Hematology Department, Hôpital Hotel Dieu, NANTES CEDEX 1, France
12Hematology Department, Centre Henri Becquerel, Rouen, France
13ICANS, Hematology Department, CHU Strasbourg, Illkirch, France
14Hematology Department, CHU de Poitiers, Poitiers, France
15Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
16Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Pessac, France
17Hematology and Transplantation, Institut Paoli-Calmettes, Aix Marseille University, Marseille, France
18Hematology Department, Sorbonne Université, Hôpital Pitié-Salpêtrière, APHP, Paris, France
19Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France
20CHU Toulouse, Toulouse, France
21Hematology Laboratory, Centre Henri Becquerel, Rouen, France
22Institut de Recherche Saint-Louis (IRSL), ALFA Group Coordination, Paris, France
23Hôpital Haut-Lévèque, FILO Group Coordination, Pessac, France
24Hôpital Avicenne, Hematology Department, AP-HP, Bobigny, France
25Department of Hematology, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM, Marseille, France
26IUCT-Oncopole, Hematology Laboratory, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
27Hematology Laboratory, CHU Lille, Lille, France
28Biostatistics Department, CHU Angers, Angers, France
29IUCT-Oncopole, Hematology Department, CHU Toulouse, Toulouse, France

4:45 PM

Himachandana Atluri, MD1, Jillian Mullin, BA, RN, MN2*, Koichi Takahashi, MD, PhD2, Sanam Loghavi, MD3, Abhishek Maiti, MD4, Koji Sasaki, MD2, Naval Daver, MD2, Yesid Alvarado Valero, MD2, Naveen Pemmaraju, MD2, Gautam Borthakur, MD2, Danielle E. Hammond, MD2, Kelly S. Chien, MD2, Alessandra Ferrajoli, MD2, Nicholas J. Short, MD2, Hussein A Abbas, MD, PhD2, Elias Jabbour5, Michael Andreeff, MD PhD2, Farhad Ravandi, MD, MBBS2, Rebecca S.S. Tidwell, MS6*, Xuemei Wang, MS6*, Marina Y. Konopleva7, Guillermo Garcia-Manero, MD2, Hagop M. Kantarjian, MD2 and Courtney D. DiNardo, MD, MSc2

1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Hematopathology, MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, MD Anderson Cancer Center, Houston, TX
5University of Texas M.D. Anderson Cancer Ctr., Houston, TX
6Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY

5:00 PM

Xiaohui Suo1*, Dongmei Wang2*, Fang Zheng3*, Suping Zhang4*, Congcong Zhang1*, Yinling Li1*, Rui Shi2*, Yan Wu2*, Sisi Yang3*, Liyun Zhao5*, Zongjiu Jiao5*, Jie Liu, MBBS, MPH6, Ling Zhang6*, Ling Li7*, Zhihua Zhang, MD8*, Xinxiao Lu9*, Linyu Yuan9*, Sifeng Gao10*, Jilei Zhang10*, Xingli Zhao11*, Guanchen Bai10*, Yingchang Mi, MD12,13 and Kaiqi Liu13,14*

1Department of Hematology, Handan Central Hospital, Handan, Hebei, China, 056000,, Handan, China
2Department of Hematology, Harrison International peace Hospital, Hengshui, Hebei, China, 053000., Hengshui, China
3Department of Hematology, Baiyun Hospital affiliated to Guizhou Medical University, Guiyang, Guizhou, China, 550000., Guiyang, China
4Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
5Department of Hematology, People Hospital of XingTai, Xing Tai, Hebei, China, 054001, Xingtai, China
6Department of Hematology, Sinopharm Tongmei General Hospital, Datong, Shanxi, China, 037003, Datong, China
7Department of Hematology, Inner Mongolia People's Hospital, Huhehaote, Neimenggu, China, 010000, Huhehaote, China
8Affiliated Hospital of Chengde Medical University, Chengde, China
9Department of Hematology, Oncology Center, Tianjin People's Hospital, No. 190 jieyuan Road, Hongqiao District, Tianjin 300121, P R China., Tianjin, China
10Department of Hematology, The Affiliated Tai'an City Central Hospital of Qingdao University, Taian, Shandong, China, 271000., Taian, China
11Tianjin People's Hospital, Tianjin, China
12State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
13Tianjin Institutes of Health Science, Tianjin, China
14National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China

5:15 PM

Jing Lu, MD1*, Shengli Xue2*, Ying Wang2*, Hai-Ping Dai2*, Xuefeng He2*, Xiaohui Hu2*, Miao Miao2*, Huiying Qiu2*, Han Yue2*, Caixia Li2*, Depei Wu2 and Suning Chen2*

1Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, AL, China
2Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China

5:30 PM

B. Douglas Smith, MD1, Curtis A Lachowiez, MD2, Alexander Joseph Ambinder, MD, MPH1, Gary Binder, MBA3*, Anne Angiolillo, MD3*, Assaf Vestin, PhD3*, Robert Paglia, MBA, RPh3*, Ravi Potluri, MBA4*, Eros Papademetriou, MA5* and Thomas W LeBlanc, MD6

1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
2Knight Cancer Institute, Oregon Health & Science University, Portland, OR
3Servier Pharmaceuticals LLC, Boston, MA
4Putnam Inizio Advisory, New York, NY
5Putnam PHMR, New York, NY
6Duke Cancer Center, Durham, NC

5:45 PM

Harry P. Erba, MD, PhD1, Herve Dombret, MD2, Alexander Perl3, Tsvetomir Mitov4*, Li Liu4*, Yasser Mostafa Kamel4*, Karima Imadalou5*, Youngsook Choi6*, Mark J. Levis, MD, PhD7 and Richard F Schlenk8*

1Duke Cancer Institute, Durham, NC
2Saint Louis Hospital, University of Paris, Paris, France
3Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA
4Daiichi Sankyo, Inc, Basking Ridge
5Daiichi Sankyo, Inc, Basking Ridge, NJ
6Daiichi Sankyo, Inc, London, United Kingdom
7Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD
8Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

*signifies non-member of ASH